M
Memento MedicinesDrug Development
Memento Medicines develops novel therapeutics for neurodegenerative diseases using proprietary drug discovery platforms.
$93MSeries A
Investor undisclosed
A $93M Series A for early-stage neuro therapeutics signals serious institutional conviction in platform-based drug discovery—this isn't a single-asset bet. If you're building in adjacent biotech (diagnostics, patient data, manufacturing), this validates that deep-tech biotech rounds are still getting funded at scale despite macro headwinds, which means your Series A bar is probably higher but the capital exists if your unit economics are defensible.